Atossa logo
May 18, 2022
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

May 09, 2022
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

Apr 27, 2022
Atossa Therapeutics to Present at the Q2 Investor Summit Conference

Apr 20, 2022
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

Mar 23, 2022
Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

Mar 08, 2022
Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

Feb 28, 2022
Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

Jan 27, 2022
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

Jan 18, 2022
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Dec 22, 2021
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

   1    2   3   4   5   6